[PMID: 9879640] PubMed record related to this compound for laboratory literature review
Twelve+ Phase 3 trials, three FDA approvals, a published CVOT in 13,165 patients, and a mature prescribing-information safety envelope
Kaufman wondered if these particular receptors may be the key in the lock that can calm down mast cells
So what we do is we take a naturally occurring hormone, we take it out, synthesize it into pharmacologic amounts, give it back to individuals, so we're able to amplify these satiety signals that someone's not quite getting, so they feel full
KLOW consolidates four individually well-researched peptides into one vial, simplifying experimental design and reducing sourcing complexity